Li Bang International Corp Inc. Current Report (Foreign Issuer)
Li Bang International Corporation Inc. reported it received a Nasdaq notice that its closing bid price has been below the $1.00 minimum for 31 consecutive business days, triggering a deficiency under Nasdaq Rule 5550(a)(2).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Li Bang International Corporation Inc. reported it received a Nasdaq notice that its closing bid price has been below the $1.00 minimum for 31 consecutive business days, triggering a deficiency under Nasdaq Rule 5550(a)(2). The notice does not immediately affect the listing; the stock continues trading on The Nasdaq Capital Market under “LBGJ.”
The company has 180 calendar days, until May 6, 2026, to regain compliance. If the bid closes at or above $1.00 for at least 10 consecutive business days within this window, Nasdaq will confirm compliance. If not, a second 180‑day period may be available, subject to meeting other initial listing standards and notifying Nasdaq of an intent to cure. The company is monitoring its bid price and evaluating options, and issued a press release on November 12, 2025.
Insights
Nasdaq bid-price deficiency with a defined 180-day cure path.
Li Bang International (LBGJ) disclosed a Nasdaq minimum bid-price deficiency after 31 consecutive business days below $1.00. The listing remains active, which preserves trading liquidity while the company works within the compliance window.
The cure requires the bid to close at or above $1.00 for 10 consecutive business days before May 6, 2026. If unmet, a second 180-day period may be available provided other initial listing standards are satisfied and the company formally indicates an intent to cure.
This is an administrative listing matter with no immediate cash impact. Outcomes depend on market pricing and any actions the company may take; subsequent disclosures may provide further detail.
AI-generated analysis. How Rhea-AI works. Not financial advice.